In August 2024, SYLKE® raised a $5.5 million Series Seed at a $50 million pre-money valuation.
Latest Stories
SYLKE® launches Global Relief: Charitable Use Program
Our charitable use program that partners with nonprofits and frontline healthcare teams to deliver SYLKE® Adhesive Wound Closure dressings where they’re needed most.
SYLKE® is now ISO 13485:2016–certified and MDSAP-audited
SYLKE® Adhesive Wound Closure is now ISO 13485:2016–certified and MDSAP-audited - supporting market access, pending regulatory approval, in the United States, Canada, Australia, Japan, and Brazil.
In March 2025, SYLKE® raised a $10.03 million Series A at a $150 million pre-money valuation.
Share:
$10.03 Million Series A